Genetic Technologies (CHIA:GTG) - Stock Price, News & Analysis

GTG Stock Overview

A molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people’s health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More details

GTG fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Shares are highly illiquid

Earnings have declined by 16.6% per year over past 5 years

Does not have a meaningful market cap (A$6M)

Shareholders have been diluted in the past year

Genetic Technologies Limited Competitors

Memphasys

ASX:MEM

AU$7.9m

OncoSil Medical

ASX:OSL

AU$31.4m

Cryosite

ASX:CTE

AU$41.7m

Proteomics International Laboratories

ASX:PIQ

AU$87.8m

Price History & Performance

Summary of all time highs, changes and price drops for Genetic Technologies
Historical stock prices
Current Share Price	AU$0.038
52 Week High	AU$0.25
52 Week Low	AU$0.038
Beta	0.48
11 Month Change	0%
3 Month Change	n/a
1 Year Change	-84.80%
33 Year Change	-93.67%
5 Year Change	-90.50%
Change since IPO	-98.42%

Recent updates

Shareholder Returns

	GTG	AU Life Sciences	AU Market
7D	0%	-6.0%	0.9%
1Y	-84.8%	8.8%	17.7%

Return vs Industry: GTG underperformed the Australian Life Sciences industry which returned 8.8% over the past year.

Return vs Market: GTG underperformed the Australian Market which returned 17.7% over the past year.

Price Volatility

Is GTG's price volatile compared to industry and market?
GTG volatility
GTG Average Weekly Movement	n/a
Life Sciences Industry Average Movement	11.2%
Market Average Movement	8.5%
10% most volatile stocks in AU Market	17.2%
10% least volatile stocks in AU Market	3.3%

Stable Share Price: GTG's share price has been volatile over the past 3 months compared to the Australian market.

Volatility Over Time: Insufficient data to determine GTG's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1987	55	Simon Morriss	genetype.com

Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people’s health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer.

Genetic Technologies Limited Fundamentals Summary

How do Genetic Technologies's earnings and revenue compare to its market cap?
GTG fundamental statistics
Market cap	AU$5.67m
Earnings (TTM)	-AU$12.02m
Revenue (TTM)	AU$9.67m

0.6x

P/S Ratio

-0.5x

P/E Ratio

Is GTG overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GTG income statement (TTM)
Revenue	AU$9.67m
Cost of Revenue	AU$3.76m
Gross Profit	AU$5.91m
Other Expenses	AU$17.93m
Earnings	-AU$12.02m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.083
Gross Margin	61.12%
Net Profit Margin	-124.24%
Debt/Equity Ratio	35.2%

How did GTG perform over the long term?

See historical performance and comparison

GTG Stock Overview

Risk Analysis

Genetic Technologies Limited Competitors

ASX:MEM

AU$7.9m

ASX:OSL

AU$31.4m

ASX:CTE

AU$41.7m

ASX:PIQ

AU$87.8m

Price History & Performance

Recent News & Updates

Full year 2024 earnings released: AU$0.091 loss per share (vs AU$0.12 loss in FY 2023)

Genetic Technologies Limited Announces Global Launch of GeneType on Wholly Owned EasyDNA Platform

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of AUD 1.71026 million.

Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of AUD 3.997793 million.

Genetic Technologies Limited Appoints Mark Ziirsen as Chief Financial Officer

Genetic Technologies Limited Announces Resignation of Kathryn Andrews as CFO

Recent updates

Full year 2024 earnings released: AU$0.091 loss per share (vs AU$0.12 loss in FY 2023)

Genetic Technologies Limited Announces Global Launch of GeneType on Wholly Owned EasyDNA Platform

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of AUD 1.71026 million.

Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of AUD 3.997793 million.

Genetic Technologies Limited Appoints Mark Ziirsen as Chief Financial Officer

Genetic Technologies Limited Announces Resignation of Kathryn Andrews as CFO

Genetic Technologies Limited Share the Power of the geneType Test in Identifying Risk and Improving the Health of Populations Worldwide

New major risk - Revenue and earnings growth

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of $2 million.

New minor risk - Shareholder dilution

Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of $11.2056 million.

Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of $2 million.

Genetic Technologies Limited Establishes Clinical Implementation Study with Breast Screen Centres Across New York, Miami and Houston

Genetic Technologies Limited to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare

Independent Non-Executive Chairman recently bought AU$80k worth of stock

New major risk - Financial position

Genetic Technologies Limited Announces Resignation of Tony Di Pietro as Chief Financial Officer

Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement

New major risk - Market cap size

Genetic Technologies Limited, Annual General Meeting, Nov 22, 2023

Genetic Technologies Limited Announces the Expanded GeneType Multi-Risk Test Is Now Available to Order in Australia

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2022)

New minor risk - Financial data availability

First half 2023 earnings released: AU$0.001 loss per share (vs AU$0 in 1H 2022)

Genetic Technologies Limited Announces Publication Highlights Genetype’S Ability to Detect Breast Cancer Earlier and Provide Data for Risk Stratification

Genetic Technologies Limited Provides Further Update on Comprehensive Risk Test for Breast & Ovarian Cancer

Genetic Technologies Limited to Launch World’s First Comprehensive Risk Test for Breast & Ovarian Cancer

Non-Independent Non-Executive Director recently sold AU$77k worth of stock

Genetic Technologies Limited Published in Plus One for Cvd & Type 2 Diabetes

Genetic Technologies Limited, Annual General Meeting, Nov 28, 2022

Genetic Technologies Limited Appoints Tony Di Pietro as Chief Financial Officer

Full year 2022 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2021)

Genetic Technologies Limited (ASX:GTG) completed the acquisition of eCommerce Business and Distribution Rights of AffinityDNA from Affinity DNA Limited.

Genetic Technologies Limited Announces Resignation of Michael Tonroe as Company Secretary

Genetic Technologies Limited Commences Initial Implementation of its geneType Risk Assessment Test at 16 Medical Practices Across the East Coast of Australia

Genetic Technologies Limited Announces the Completion of an Independently Developed and Validated Customisable Budget Impact Model

Genetic Technologies Limited (ASX:GTG) entered into an agreement to acquire eCommerce Business and Distribution Rights of AffinityDNA from Affinity Dna Limited for £0.555 million

Genetic Technologies Limited Announces GeneType Multi-Test Approves for Commercial Release

High number of new and inexperienced directors

Full year 2021 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2020)

Genetic Technologies Limited (ASX:GTG) completed the acquisition of General Genetics Corporation from BelHealth Investment Fund, L.P. managed by BelHealth Investment Partners, LLC.

Company Secretary Justyn Stedwell has left the company

Genetic Technologies Limited Confirms the Launch of GTG's Covid-19 Serious Disease Risk Test (`Covid-19 Risk Test') by US Based Infinity Biologix LLC

Genetic Technologies Limited Provides COVID-19 Risk Test Launch Update

Genetic Technologies Limited Signs 3-Year US Licence Agreement for COVID Risk Test

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of $6.5625 million.

Genetic Technologies Limited Provides Update on Its COVID-19 Disease Severity Risk Test and Expansion into Germline Testing

Genetic Technologies Limited Announces Management Changes

Genetic Technologies Secures US and ANZ Distribution Rights for PREDICTIX

Genetic Technologies Limited, Annual General Meeting, Dec 10, 2020

Genetic Technologies Limited to Report Q4, 2020 Results on Oct 30, 2020

Full year earnings released - AU$0.0015 loss per share

Genetic Technologies Provides Update on COVID-19 Risk Test

Full year earnings released - AU$0.0015 loss per share

Full year earnings released - AU$0.0015 loss per share

Genetic Technologies Regains Compliance with Nasdaq Stockholders Equity Requirement

Full year earnings released - AU$0.0015 loss per share

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of $5.125 million.

Shareholder Returns

Price Volatility